GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:21 23/05/2024 BST			5-day change	1st Jan Change
1,778 ^GBX	-0.59%		-1.90%	+22.60%

05-23	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
05-23	Sector Update: Health Care	MT

GSK Says Considering Potential Deal Including Merger Of Its Consumer Healthcare Unit

November 29, 2018 at 05:00 am

GlaxoSmithKline plc (LSE:GSK) confirmed that consideration is being given to a potential transaction that includes a merger of GlaxoSmithKline Consumer Healthcare Limited (BSE:500676). Majority of Horlicks and other GlaxoSmithKline nutrition products sales are generated in India by GlaxoSmithKline Consumer Healthcare Limited.

Latest news about GSK plc

Sector Update: Health Care Stocks Retreat Late Afternoon	05-23	MT
Sector Update: Health Care	05-23	MT
GSK's Zantac Didn't Cause Woman's Cancer, Chicago Jury Verdict Says	05-23	MT
GSK's Zantac Cleared in Chicago Jury Trial for Alleged Colon Cancer Link	05-23	MT
GSK's Zantac Cleared in Chicago Jury Trial for Alleged Colon Cancer Link	05-23	MT
GSK on Zantac Litigation Says Will Continue To "Vigorously Defend" Itself Against All Claims	05-23	RE
GSK - VERDICT CONSISTENT WITH SCIENTIFIC CONSENSUS THAT THERE IS…	05-23	RE
GSK: NEXT ZANTAC TRIAL DUE TO START IN ILLINOIS DISMISSED…	05-23	RE
GSK: JURY IN VALADEZ CASE IN ILLINOIS STATE COURT FINDS GSK NOT…	05-23	RE
GSK: STATEMENT: ZANTAC (RANITIDINE) LITIGATION - VALADEZ AND WIL…	05-23	RE
Health Care Up as Vaccine Makers Gain - Health Care Roundup	05-22	DJ
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	05-22	MT
News Highlights : Top Company News of the Day - Wednesday at 1 AM ET	05-22	DJ
GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies	05-21	MT
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- 2nd Update	05-21	DJ
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET	05-21	DJ
GSK Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- Update	05-21	DJ
GSK: positive results for depemokimab in severe asthma	05-21	CF
GSK's depemokimab asthma treatment meets endpoints in latest trials	05-21	AN
GSK's experimental drug shows promise in reducing severe asthma attacks	05-21	RE
GSK's Asthma Drug Reduces Severe Attacks in Late-stage Studies	05-21	MT
GSK Sees Positive Results for Severe Asthma Treatment Depemokimab	05-21	DJ
GSK's asthma drug shows promise in reducing severe attacks	05-21	RE
GSK Reports Positive Phase III Asthma Results For Depemokimab	05-21	RE
AstraZeneca aims for $80 bln in total revenue by 2030	05-21	RE

Chart GSK plc

Duration

Period

More charts

Company Profile

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Sector

Pharmaceuticals

Calendar

05/06/2024 - BNP Paribas Exane CEO Conference

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK plc : Back on track

May 03, 2024 at 10:17 am

GSK PLC : Encouraging start to 2024; guidance raised

May 01, 2024 at 04:38 pm

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.78 GBP

Average target price

20.32 GBP

Spread / Average Target

+14.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+22.60%	92.82B
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

GSK Says Considering Potential Deal Including Merger Of Its Consumer Healthcare Unit

EPS Revisions